Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab and Vinorelbine in HER2-negative breast cancer with HER2-positive CTCs
NCT01185509Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2010
- Primary completion
- Jan 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in breast cancer, sponsored by Dana-Farber Cancer Institute. Started Nov 2010; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01185509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01185509.